GlassScriptPhysician profile
Anjali G Bal
NPI 1164818910
$6,521.51
in general payments reported to CMS, 2019-2025
28 companies · $2,316 in 2025
The $2,316 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $95.74 · 2022: $597 · 2023: $1,516 · 2024: $1,997 · 2025: $2,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,821 · Education: $7.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,820.69 |
| Education | $7.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,228.92 | 2022-2025 | Evenity, Enbrel, Otezla |
| Abbvie INC. | $859.22 | 2021-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $485.87 | 2022-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $483.70 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $458.96 | 2022-2025 | |
| Janssen Biotech, INC. | $450.56 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| E.R. Squibb & Sons, L.L.C. | $331.48 | 2022-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $251.14 | 2021-2025 | Saphnelo |
| Ani Pharmaceuticals, INC. | $204.32 | 2022-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $202.95 | 2022-2025 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.83 | 2022-2025 | Ofev, Cyltezo |
| Radius Health, INC. | $188.89 | 2024-2025 | Tymlos |
| Fresenius Kabi USA, LLC | $176.59 | 2023-2025 | Idacio, Tyenne |
| Aurinia Pharma U.S., INC. | $167.94 | 2021-2024 | Lupkynis |
| Organon LLC | $134.76 | 2023-2025 | Renflexis, Hadlima |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $122.21 | 2024-2025 | Actemra, Rituxan |
| Glaxosmithkline, LLC. | $88.17 | 2023-2025 | Benlysta, Ojjaara, Blenrep |
| Kyowa Kirin, INC. | $81.51 | 2024 | Crysvita |
| Genzyme Corporation | $74.34 | 2023-2025 | |
| Zimmer Biomet Holdings, INC. | $62.84 | 2025 | Gel-One Cross-Linked Hyaluronate |
| Mallinckrodt Hospital Products INC. | $61.96 | 2024-2025 | Acthar |
| Sandoz INC. | $55.36 | 2025 | Hyrimoz, Jubbonti |
| Scilex Pharmaceuticals INC. | $44.32 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $43.10 | 2023 | Arcalyst |
| Sobi, INC | $21.02 | 2025 | |
| Almatica Pharma LLC | $19.44 | 2025 | Teriparatide |
| Tonix Medicines, INC. | $16.14 | 2025 | Tonmya |
| Celltrion USA INC. | $15.97 | 2024 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjali Bal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.